336 related articles for article (PubMed ID: 26658891)
1. Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin.
Kim SJ; Kim JH; Ki CS; Ko YH; Kim JS; Kim WS
Ann Oncol; 2016 Mar; 27(3):508-13. PubMed ID: 26658891
[TBL] [Abstract][Full Text] [Related]
2. Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications.
Kim JH; Kim WS; Park C
Antiviral Res; 2021 May; 189():105063. PubMed ID: 33741394
[TBL] [Abstract][Full Text] [Related]
3. Reply to the letter to the editor 'Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma' by Tan et al.
Kim SJ; Kim WS
Ann Oncol; 2016 Nov; 27(11):2133-2134. PubMed ID: 27502713
[No Abstract] [Full Text] [Related]
4. Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
Shin DY; Kim A; Kang HJ; Park S; Kim DW; Lee SS
Cancer Lett; 2015 Aug; 364(2):89-97. PubMed ID: 25790907
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report.
Ritchie D; Piekarz RL; Blombery P; Karai LJ; Pittaluga S; Jaffe ES; Raffeld M; Janik JE; Prince HM; Bates SE
Haematologica; 2009 Nov; 94(11):1618-22. PubMed ID: 19608677
[TBL] [Abstract][Full Text] [Related]
7. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
Foss F; Horwitz S; Pro B; Prince HM; Sokol L; Balser B; Wolfson J; Coiffier B
J Hematol Oncol; 2016 Mar; 9():22. PubMed ID: 26965915
[TBL] [Abstract][Full Text] [Related]
8. Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma.
Cho J; Kim SJ; Park S; Yoo KH; Ki CS; Ko Y; Kim WS
Ann Hematol; 2018 Aug; 97(8):1427-1436. PubMed ID: 29627879
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus-negative extranodal "true" natural killer-cell lymphoma harbouring a KDM6A mutation.
Tsuyama N; Asaka R; Dobashi A; Baba S; Mishima Y; Ueda K; Oguchi M; Tsuji H; Hatake K; Takeuchi K
Hematol Oncol; 2018 Feb; 36(1):328-335. PubMed ID: 28695659
[TBL] [Abstract][Full Text] [Related]
10. Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol.
Wang XX; Li PF; Bai B; Gao Y; Rong QX; Cai QQ; Lin SX; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
Leuk Lymphoma; 2019 Aug; 60(8):1917-1925. PubMed ID: 30646796
[TBL] [Abstract][Full Text] [Related]
11. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.
Foss F; Duvic M; Lerner A; Waksman J; Whittaker S
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):637-643. PubMed ID: 27637428
[TBL] [Abstract][Full Text] [Related]
12. Romidepsin: in the treatment of T-cell lymphoma.
Yang LP
Drugs; 2011 Jul; 71(11):1469-80. PubMed ID: 21812508
[TBL] [Abstract][Full Text] [Related]
13. The discovery and development of romidepsin for the treatment of T-cell lymphoma.
Smolewski P; Robak T
Expert Opin Drug Discov; 2017 Aug; 12(8):859-873. PubMed ID: 28641053
[TBL] [Abstract][Full Text] [Related]
14. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
[TBL] [Abstract][Full Text] [Related]
15. HKDC1 C-terminal based peptides inhibit extranodal natural killer/T-cell lymphoma by modulation of mitochondrial function and EBV suppression.
Chen Q; Feng J; Wu J; Yu Z; Zhang W; Chen Y; Yao P; Zhang H
Leukemia; 2020 Oct; 34(10):2736-2748. PubMed ID: 32203147
[TBL] [Abstract][Full Text] [Related]
16. L-Asparaginase monotherapy for EBV-positive T/NK lymphoproliferative diseases: A pilot Study.
Jinta M; Imadome K; Komatsu H; Yoshimori M; Kurata M; Fujiwara S; Miura O; Arai A
J Med Dent Sci; 2015 Mar; 62(1):1-9. PubMed ID: 26111530
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.
Siddiquey MN; Nakagawa H; Iwata S; Kanazawa T; Suzuki M; Imadome K; Fujiwara S; Goshima F; Murata T; Kimura H
Cancer Sci; 2014 Jun; 105(6):713-22. PubMed ID: 24712440
[TBL] [Abstract][Full Text] [Related]
18. Genotypic analysis and latent membrane protein 1 expression of Epstein-Barr virus in extranodal NK/T-cell lymphoma from Northern Chinese patients.
Wang H; Li H; Xing X; Zhao C; Luo B
Arch Virol; 2015 Aug; 160(8):2071-4. PubMed ID: 26008210
[TBL] [Abstract][Full Text] [Related]
19. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.
Bates SE; Eisch R; Ling A; Rosing D; Turner M; Pittaluga S; Prince HM; Kirschbaum MH; Allen SL; Zain J; Geskin LJ; Joske D; Popplewell L; Cowen EW; Jaffe ES; Nichols J; Kennedy S; Steinberg SM; Liewehr DJ; Showe LC; Steakley C; Wright J; Fojo T; Litman T; Piekarz RL
Br J Haematol; 2015 Jul; 170(1):96-109. PubMed ID: 25891346
[TBL] [Abstract][Full Text] [Related]
20. Romidepsin for cutaneous T-cell lymphoma.
Prince HM; Dickinson M
Clin Cancer Res; 2012 Jul; 18(13):3509-15. PubMed ID: 22535155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]